Managing Apoptosis in Lung Diseases using Nano-assisted Drug Delivery System

Monu K Shukla; Amit Dubey; Sadanand Pandey; Sachin K Singh; Gaurav Gupta; Parteek Prasher; Dinesh K Chellappan; Brian G Oliver; Deepak Kumar; Kamal Dua

doi:10.2174/1381612828666220413103831

Managing Apoptosis in Lung Diseases using Nano-assisted Drug Delivery System

Curr Pharm Des. 2022;28(39):3202-3211. doi: 10.2174/1381612828666220413103831.

Authors

Monu K Shukla¹, Amit Dubey^{2

3}, Sadanand Pandey⁴, Sachin K Singh^{5

6}, Gaurav Gupta^{3

7

8}, Parteek Prasher⁹, Dinesh K Chellappan¹⁰, Brian G Oliver^{11

12}, Deepak Kumar¹, Kamal Dua^{6

12

13}

Affiliations

¹ Department of Pharmaceutical Chemistry, School of Pharmaceutical Sciences, Shoolini University, Solan-173229, Himachal Pradesh, India.
² Computational Chemistry and Drug Discovery Division, Quanta Calculus Pvt. Ltd., Kushinagar-274203, India.
³ Department of Pharmacology, Saveetha Dental College and Hospital, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamil Nadu 602105, India.
⁴ Department of Chemistry, College of Natural Sciences, Yeungnam University, Gyeongsan, Gyeongbuk, 38541, South Korea.
⁵ School of Pharmaceutical Sciences, Lovely Professional University, Phagwara-144411, Punjab, India.
⁶ Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo NSW 2007, Australia.
⁷ School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur, 302017, India.
⁸ Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, 248007, India.
⁹ Department of Chemistry, University of Petroleum & Energy Studies, Dehradun 248007, India.
¹⁰ Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.
¹¹ School of Life Sciences, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
¹² Woolcock Institute of Medical Research, University of Sydney, Sydney, New South Wales, NSW 2037, Australia.
¹³ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia.

PMID: 35422206
DOI: 10.2174/1381612828666220413103831

Abstract

Several factors exist that limit the efficacy of lung cancer treatment. These may be tumor-specific delivery of therapeutics, airway geometry, humidity, clearance mechanisms, presence of lung diseases, and therapy against tumor cell resistance. Advancements in drug delivery using nanotechnology based multifunctional nanocarriers, have emerged as a viable method for treating lung cancer with more efficacy and fewer adverse effects. This review does a thorough and critical examination of effective nano-enabled approaches for lung cancer treatment, such as nano-assisted drug delivery systems. In addition, to therapeutic effectiveness, researchers have been working to determine several strategies to produce nanotherapeutics by adjusting the size, drug loading, transport, and retention. Personalized lung tumor therapies using sophisticated nano modalities have the potential to provide great therapeutic advantages based on individual unique genetic markers and disease profiles. Overall, this review provides comprehensive information on newer nanotechnological prospects for improving the management of apoptosis in lung cancer.

Keywords: Lung cancer; apoptosis; lung diseases; nano-drug delivery systems; nanoparticles; nanotechnology.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Apoptosis
Drug Carriers
Drug Delivery Systems / methods
Humans
Lung Neoplasms* / drug therapy
Nanoparticle Drug Delivery System
Nanoparticles* / therapeutic use
Nanotechnology

Substances

Nanoparticle Drug Delivery System
Drug Carriers